The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

Fri, 24th Jun 2016 09:49

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday, following the UK's vote to leave the European Union.
----------
FTSE 100 - WINNERS
----------
Randgold Resources, up 15%, Fresnillo, up 11%. The miners were up on the higher gold price, quoted at USD1,311.39 an ounce compared to USD1,265.12 at the London equities close Thursday. The precious metal reached a 2016 record high earlier Friday at USD1,359.19 an ounce.

GlaxoSmithKline, up 1.1%, Mediclinic International, up 0.8%, AstraZenenca, up 0.3%. Large-cap pharmaceutical companies stand to benefit from a weak pound, as much of their revenue is in dollars and other non-UK or European currencies. Sterling was quoted at USD1.3869 at mid-morning, having touched a low it hasn't seen since 1985 at USD1.3227 earlier Friday. However, Mike Thompson, chief executive officer of the Association of the British Pharmaceutical Industry, said the UK's vote to leave the EU "creates immediate challenges" for the industry, and smaller drug shares were sharply lower, including Tiziana Life Sciences, down 19%, Evgen Pharma, down 16%, and Oxford Pharmascience Group, down 13%.
----------
FTSE 100 - LOSERS
----------
Taylor Wimpey, down 24%, Persimmon, down 24%, Barratt Developments, 21%. "The debate over what the EU referendum means for the outlook for the UK will last much longer than today, but for now we offer the conclusion that the outcome is bad for housebuilders' shares as the combination of slowing GDP, rising longer term rates and political uncertainty is like Kryptonite for that group of shares," said Liberum analyst Charlie Campbell.

Lloyds Banking Group, down 21%, Aviva, down 20%, Barclays, down 19%, Royal Bank of Scotland, down 18%. The financial services companies had been trading particularly higher in the lead up to the vote. In the week prior to the referendum the sector FTSE 350 banking index was up 12%, however on Friday morning index was down 10%.

International Consolidated Airlines Group, down 19%. The British Airways, Aer Lingus and Iberia parent company issued a profit warning for 2016 after the UK vote. "Following the outcome of the referendum, and given current market volatility, while IAG continues to expect a significant increase in operating profit this year, it no longer expects to generate an absolute operating profit increase similar to 2015," IAG said in a statement. EasyJet was down 19%.

ITV, down 18%. The broadcaster was by far the European media stock most exposed to Brexit risk, with 73% of its revenue coming from advertising, according to Societe Generale, which cut its rating on the company to Sell from Hold.
----------
FTSE 250 - WINNERS
----------
Gold miners - Acacia Mining, up 15%, Centamin, up 7.8%, Polymetal International, up 4.8%.
----------
FTSE 250 - LOSERS
----------
Banks - Aldermore Group, down 24%, Virgin Money Holdings, down 22%, Shawbrook Group, down 21%.

Housebuilders - Crest Nicholson Holdings, down 22%, Derwent London, down 22%, Bellway, down 21%, Redrow down 14%.

Recruiters - Hays, down 23%, Page Group, down 18%. Recruitment firms earlier had warned of a slow down in hiring in the run up to the referendum.
----------
MAIN MARKET AND AIM - LOSERS
----------
Proxama, down 43% at 0.429 pence. The marketing and mobile payment solutions company reported a wider pretax loss in 2015, although revenue rose, as it announced it will raise GBP2 million in a share placing. The company said its pretax loss widened to GBP6.1 million in 2015 from GBP5.9 million in 2014, despite revenue multiplying to GBP2.5 million from GBP650,978. Profit was hindered by an increase in administrative expenses to GBP8.6 million from GBP5.8 million, but revenue was boosted by good progress within the digital payments division. Proxama also said it will raise GBP2 million through the placing of 666.7 million shares at 0.3 pence each. Proxama said the placing price represents a discount of approximately 59% to the closing price of 0.725 pence on Thursday, and certain directors of the company have indicated an intention to invest GBP260,000 as part of the placing.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
7 Aug 2019 11:47

Evgen Pharma Gets European Patent Covering Composition Of SFX-01

(Alliance News) - Evgen Pharma PLC on Wednesday said it has secured further intellectual property rights in Europe for SFX-01.The drug development company, focused on breast cancer and said

Read more
5 Aug 2019 11:45

Evgen Pharma To Collaborate With King's College And British Heart

(Alliance News) - Evgen Pharma PLC said Monday that it backs the new research collaboration between King's College London and the British Heart Foundation.The collaboration is how - - a

Read more
18 Jul 2019 13:00

Evgen Pharma Outlook Confident As Progresses Programmes Development

(Alliance News) - Evgen Pharma PLC on Thursday expressed confidence for the year ahead as it continued to progress on the development of its clinical programmes.Ahead of its annual general

Read more
13 Jun 2019 12:21

Evgen Pharma Annual Loss Fractionally Wider On Small Expense Rise

(Alliance News) - Evgen Pharma PLC on Thursday said its loss marginally widened in its most recent financial year due to slightly higher expenses as drug development continues.Clinical drug

Read more
13 Jun 2019 09:03

Evgen Pharma losses edge wider on higher costs

(Sharecast News) - Evgen Pharma on Thursday reported a slightly widened annual loss due to a cost increase, with its results in line with expectations as its drugs remain in the development stage.

Read more
17 Apr 2019 13:17

Evgen Pharma Raises GBP5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it raised GBP5.0 million via issue of shares in an oversubscribed placing.The clinical stage drug development company issued 13.1 at

Read more
25 Mar 2019 10:23

Good Headline Results From Evgen Pharma Breast Cancer Study Of SFX-01

LONDON (Alliance News) - Evgen Pharma PLC on Monday announced positive headline results from its phase two Stem trial of SFX-01 in advanced breast cancer.Shares in the clinical-stage drug -

Read more
18 Mar 2019 11:10

Evgen Pharma Expects STEM Trial Read-Out Next Week

LONDON (Alliance News) - Evgen Pharma PLC on Monday said it expects the final read-out of its STEM trial in metastatic breast cancer to be announced early next week, in line with its guidance of

Read more
5 Mar 2019 11:35

Study Of Evgen Pharma's SFX-01 Multiple Sclerosis Drug Shows Promise

LONDON (Alliance News) - Clinical stage drug developer Evgen Pharma PLC on Tuesday said a study has been published showing that its lead product, SFX-01, reduces residual disability in a model of

Read more
5 Feb 2019 09:18

Evgen Pharma Finishes Patient Recruitment For Stroke Treatment Trial

LONDON (Alliance News) - Evgen Pharma PLC on Tuesday said it has completed patient recruitment in its SAS phase II trial for proposed treatment SFX-01.SFX-01 is a planned treatment for a an

Read more
12 Dec 2018 11:11

Evgen Pharma Interim Loss Widens As It Progresses New Drug Trials

LONDON (Alliance News) - Evgen Pharma PLC on Wednesday said its interim loss widened slightly for its most recent half as it focuses on advancing trials.For the six month to September 30, a

Read more
12 Dec 2018 10:10

Evgen Pharma's loss widens amid excitement over cancer treatment

(Sharecast News) - Evgen Pharma's shares stumbled on Wednesday after its interim loss before tax expanded, though the company was "delighted" by progress in treatment developments.

Read more
23 Oct 2018 12:55

David And Monique Newlands Build 5% Stake In Evgen Pharma (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Tuesday that David and Monique Newlands now own 5.06% stake in the company.The Newlands' holding before the transaction, if any, was not

Read more
18 Oct 2018 10:26

Evgen Pharma Raises GBP750,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it raised GBP750,000 via share placing.The company issued 5.6 million shares at 13.5p. Shares in the drug development company were at

Read more
11 Sep 2018 12:51

Tueday broker round-up

(Sharecast News) - JD Wetherspoons: Berenberg upgrades to buy with a target price of 1,450p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.